1. Introduction: The Ebola Diagnostic Challenge
Ebola virus disease (EVD) remains one of the most lethal viral hemorrhagic fevers known to medicine, with case fatality rates reaching 25-90% depending on the species and outbreak context. Rapid, on-site diagnosis is critical for outbreak containment — every hour of delay in identifying an infected individual increases the risk of community transmission.
While PCR remains the gold standard for Ebola confirmation, it requires laboratory infrastructure, trained personnel, and 1-3 hours of processing time. In resource-limited outbreak settings across Central and West Africa, rapid diagnostic tests (RDTs) that can deliver results in 10-15 minutes from a fingerstick blood sample are essential frontline tools.
The success of any Ebola RDT hinges on one critical choice: which viral protein to target. The Ebola virus genome encodes seven structural and non-structural proteins, but only a subset are viable antigen targets for immunoassay-based detection. This review focuses on the nucleoprotein (NP) — the most abundant protein in the virion and arguably the most strategically important target for Ebola antigen detection.
"With approximately 3,200 copies per virion versus ~40 for VP40, Ebola nucleoprotein offers an 80-fold numerical advantage as an antigen detection target."
2. Molecular Profile of Ebola Nucleoprotein
Ebola virus NP is the largest nucleoprotein among all non-segmented negative-stranded (NNS) RNA viruses. Understanding its molecular properties is essential for antibody development and assay design.
| Property | Value | Significance |
|---|---|---|
| Gene | NP (first gene, 3' end) | Most abundantly transcribed viral gene |
| Amino acids | 739 aa | Largest NP among NNS RNA viruses |
| Molecular weight | ~104 kDa (monomer) | Monomeric in solution; oligomerizes upon RNA binding |
| Copies per virion | ~3,200 | ~80x more abundant than VP40 (~40 copies) |
| Glycosylation | O-linked | Not N-glycosylated; may affect epitope accessibility |
| RNA binding | Non-specific (viral + host RNA) | Strong affinity for RNA; remains RNA-bound in extracellular vesicles |
| Subcellular location | Cytoplasm (inclusion bodies) | Not processed through Golgi; retained in cytoplasmic viral factories |
| Structural domains | N-terminal (1-450): oligomerization + RNA binding C-terminal (451-739): virion incorporation |
N-terminal essential for self-assembly and nucleocapsid formation |
| PDB structure | 5Z9W (NP-RNA complex), 8Y9J (nucleocapsid) | Cryo-EM structures available for antibody epitope mapping |
2.1 Functional Domains
Functional mapping studies using deletion mutants have revealed two major functional regions:
- N-terminal half (aa 1-450): This region is hydrophobic and contains the sequences responsible for NP-NP self-interaction (oligomerization) and RNA binding. Critically, amino acids 1-450 are necessary and sufficient for forming NP tube-like structures in vitro, which serve as scaffolds for nucleocapsid assembly.
- C-terminal half (aa 451-739): This hydrophilic region is required for complete nucleocapsid-like structure formation (together with aa 1-450) and is thought to mediate NP incorporation into virions through interaction with VP40.
Key Point for Antibody Developers
NP contains multiple non-overlapping epitope regions, making it amenable to sandwich immunoassay formats. The N-terminal domain (particularly aa 1-450) and C-terminal domain (aa 451-739) are structurally distinct, enabling development of matched antibody pairs that bind simultaneously to the same NP molecule.
3. Three Forms of NP in Patient Blood
One of the most frequently asked questions in Ebola antigen diagnostics is: what form does NP actually take in the bloodstream? The answer is not a single form — NP exists in at least three distinct states during active EVD infection, and all three contribute to what an RDT ultimately detects.
4. Inside the Virion: NP in the Nucleocapsid
The dominant form of NP in blood is within intact virions circulating during active viremia. Ebola virus is a filamentous, enveloped virus belonging to the Filoviridae family. Its structure, from outside to inside, is organized as follows:
- Viral envelope: A lipid bilayer derived from the host cell membrane, studded with GP (glycoprotein) trimers that mediate viral attachment and entry.
- VP40 matrix layer: Located just beneath the envelope, VP40 serves as the structural matrix protein that drives virion assembly and budding. Only ~40 copies per virion.
- Nucleocapsid (the core): A helical structure composed of NP tightly bound to the viral genomic RNA (19 kb, negative-sense, single-stranded). This helical NP-RNA complex forms the central axis of the virion, with VP24 and VP35 bound externally. Approximately 3,200 copies of NP per virion.
The nucleocapsid helix was recently resolved to 4.6 Å resolution by cryo-EM (Nature Communications, 2025), revealing that the repeating unit consists of two NP molecules paired with a VP24 molecule, with VP35 bridging adjacent NP molecules during RNA synthesis. This high-resolution structure (PDB: 8Y9J) provides a valuable reference for rational antibody epitope selection.
During peak viremia, patients can harbor 105 to 1010 viral RNA copies/mL of blood, with higher titers correlating with fatal outcomes. At 3,200 NP molecules per virion, even a modest viral load of 106 copies/mL translates to roughly 3.2 × 109 NP molecules per milliliter of blood — an enormous antigen reservoir.
VP35's Chaperone Role
Inside infected cells, VP35 binds to and stabilizes monomeric NP, keeping it soluble and preventing premature oligomerization. Only when NP is recruited to the site of viral RNA replication does VP35 release NP, allowing it to cooperatively bind viral RNA and form the nucleocapsid helix. This chaperone mechanism ensures that NP-RNA complexes form only at the right time and place during the viral life cycle.
5. Extracellular Vesicles: A Hidden Reservoir
A relatively recent and increasingly important discovery is that Ebola-infected cells release extracellular vesicles (EVs) containing viral proteins, including NP. This finding, documented by Fitzgerald et al. (2020) and subsequent studies, adds a second dimension to our understanding of NP antigenemia.
5.1 What Are Extracellular Vesicles?
EVs are lipid bilayer-enclosed particles released by virtually all cell types. They range from ~30 nm to ~1,000 nm in diameter and serve as intercellular communication vehicles. In the context of Ebola infection, EVs carry viral proteins that can disseminate throughout the body independently of intact virions.
5.2 How NP Gets Packaged into EVs
Research has identified three mechanisms by which NP enters EVs during Ebola infection:
| Mechanism | Timing | Description |
|---|---|---|
| Viral entry co-option | 1-6 hours post-infection | VP40 and GP from the entering virion remain in the endosome. When this endosome undergoes inward budding, viral proteins become integrated into intraluminal vesicles (ILVs) that can be released as exosomes. |
| ESCRT-mediated exosome packaging | 24-30+ hours post-infection | VP40 is ubiquitinated and packaged into maturing ILVs via the ESCRT complex. GP enters multivesicular bodies (MVBs) via Golgi transport. NP (likely RNA-bound) is packaged through an as-yet-uncharacterized mechanism. |
| Microvesicle budding | 24-30+ hours post-infection | VP40, GP, and NP assemble at the plasma membrane but bud as spherical microvesicles (host-driven) rather than filamentous virions (VP40-driven). |
5.3 NP Properties in EVs
NP inside EVs exhibits a distinctive property: it can bind not only viral RNA but also host RNA of various sizes and functional characteristics. This non-specific RNA binding capacity means that EV-associated NP may carry host-derived RNA fragments, potentially influencing its conformational state and epitope accessibility.
The three viral proteins confirmed in EVs are VP40, GP, and NP. It has not yet been determined whether VP24, VP30, VP35, or the L polymerase are also packaged, though the large size of L likely excludes it from EVs under 220 nm.
Immune Evasion Implication
EV-associated viral proteins may act as antibody decoys, absorbing neutralizing antibodies away from intact virions. EVs can also carry pro-inflammatory cytokines (TGF-β1, IL-15, MCP-1, IFN-γ) and travel to distant tissues, potentially contributing to systemic immune dysregulation observed in severe EVD.
6. Free NP from Cell Lysis: Direct Antigenemia
The third form of NP in blood is the most straightforward conceptually: free NP released directly from lysed or apoptotic infected cells. Ebola virus causes extensive cytopathic effects, and cell death is a hallmark of severe infection.
6.1 Source of Free NP
Inside infected cells, NP accumulates in large quantities within viral inclusion bodies — cytoplasmic structures where viral RNA synthesis and nucleocapsid assembly occur. These inclusion bodies contain:
- NP-RNA helical tubes (diameter ~20-25 nm, formed by NP self-assembly)
- Complete nucleocapsid-like structures (diameter ~50 nm, formed by NP + VP35 + VP24)
- Viral RNA at various stages of replication
When infected cells undergo necrosis, apoptosis, or pyroptosis, the contents of these inclusion bodies are released en masse into the extracellular space and subsequently into the bloodstream. The result is free NP-RNA complexes and NP aggregates circulating in plasma.
6.2 Evidence from Antigen-Capture ELISA
Antigen-capture ELISA studies on Ebola-infected primate serum samples confirm that NP is detectable in blood. Notably, these assays use sample preparation buffers containing 1% Triton X-100, a detergent that disrupts both viral envelopes and cell membranes. This solubilization step is essential for releasing NP from all three forms (virion-encapsulated, EV-encapsulated, and aggregated) into a form accessible to capture antibodies.
The fact that NP is detectable by ELISA in serum — even without a dedicated virion lysis step beyond the standard detergent-containing buffer — suggests that a significant fraction of NP exists either as free protein or in readily disruptable complexes in the blood of infected individuals.
7. NP vs. VP40 vs. GP: Target Comparison for RDTs
The choice of antigen target fundamentally determines the analytical sensitivity and clinical performance of an Ebola RDT. Three viral proteins have been used as RDT targets:
| Parameter | NP (Nucleoprotein) | VP40 (Matrix Protein) | GP (Glycoprotein) |
|---|---|---|---|
| Copies per virion | ~3,200 | ~40 | ~450 (as trimers) |
| Molecular weight | ~104 kDa | ~40 kDa | ~150 kDa (GP1,2) |
| Location in virion | Inner core (nucleocapsid) | Matrix layer (mid) | Surface envelope |
| Accessibility | Requires envelope disruption | Requires envelope disruption | Surface-exposed (no disruption needed) |
| Cross-species reactivity | High (ZEBOV, SUDV, BDBV, TAFV) | Moderate | Variable (species-specific) |
| Epitope multiplicity | Very high (739 aa, multiple domains) | Low (limited surface area) | Moderate (heavily glycosylated, shielded) |
| Soluble forms in blood | Free NP-RNA complexes from lysis; EV-associated NP | EV-associated VP40 | sGP, ssGP, shed GP (all actively secreted) |
| Best performing RDT | QuickNavi-Ebola: 85% sensitivity | OraQuick: 57-69% sensitivity | SD Q Line: multi-target |
| Key advantage | Highest copy number; strong antigenicity; cross-species epitopes | Simple matrix protein; easy to express | Surface-accessible; multiple soluble forms |
NP: The Abundance Leader
~3,200 copies per virion gives NP a massive numerical advantage. More copies = more antibody binding events = stronger signal at lower viral loads.
NP: Cross-Species Epitopes
Conserved regions across ZEBOV, SUDV, BDBV, and TAFV enable pan-Ebola detection from a single test, which VP40 cannot match.
NP: Multi-Domain Structure
Large size (739 aa) with distinct N- and C-terminal domains enables matched antibody pair development for sandwich assays.
8. Implications for RDT Design
Understanding that NP exists in three forms has direct practical implications for lateral flow RDT design:
8.1 Buffer Formulation Is Critical
Since the majority of NP is sequestered inside intact virions and EVs, the RDT running buffer must contain detergents or surfactants capable of disrupting lipid membranes. Common components include:
- Non-ionic detergents (e.g., Triton X-100, Tween-20): Disrupt viral envelopes and EV membranes without denaturing NP epitopes
- Chaotropic agents (e.g., urea, guanidine): Help dissociate NP-RNA complexes, exposing additional epitopes
- Blocking proteins (e.g., BSA, casein): Prevent non-specific binding to the nitrocellulose membrane
8.2 Sample Type Considerations
All three NP forms are present in EDTA whole blood, plasma, and serum. However, whole blood is the preferred sample for point-of-care RDTs because:
- It requires no centrifugation or processing
- It captures NP from all three forms (virion-bound, EV-bound, and free)
- It can be collected via fingerstick for field deployment
Design Caution
The NP detected by RDTs is actually the aggregate of NP from all three blood forms. The detergent in the running buffer disrupts virions and EVs, releasing NP-RNA complexes. The detection antibody must therefore recognize NP in its partially denatured or solubilized state, not necessarily in its native nucleocapsid conformation. This is why antibody screening should include NP that has been detergent-treated, not only native NP.
8.3 The Hook Effect
At extremely high NP concentrations (Ct < 15), the "hook effect" or prozone phenomenon can cause false-negative results. In the Denka QuickNavi-Ebola clinical evaluation (DRC, 928 patients), one false-negative case was attributed to the hook effect at Ct 13.9. RDT design should include controls or dilution protocols to mitigate this risk.
9. Clinical Evidence: NP-Targeting RDT Performance
The clearest evidence for NP's superiority as an RDT target comes from head-to-head clinical evaluations:
| RDT (Manufacturer) | Target | Sensitivity | Specificity | Clinical Setting |
|---|---|---|---|---|
| QuickNavi-Ebola (Denka Seiken) |
NP (exclusive) | 85.0% (68/80) | 99.8% (846/848) | DRC outbreak, 928 patients, vs GeneXpert |
| OraQuick Ebola (OraSure) |
VP40 | 57.4% (whole blood) 93.2% (plasma) |
99.6% | Multiple field evaluations |
| ReEBOV RDT (Corgenix) |
VP40 | 91.8% (operational) 74.2% (research) |
84.6-100% | Sierra Leone & Guinea |
| Coris Ebola Ag K-SeT (Coris BioConcept) |
VP40 | 69.2% (Ct < 30) 84.6% (Ct < 25) |
99.6% | DRC field evaluation |
| SD Q Line Ebola Zaire Ag (SD Biosensor) |
GP + NP + VP40 | 74.3% (Ct < 30) | 99.5% | WHO EUL listed |
The QuickNavi-Ebola, which exclusively targets NP, achieved the highest combined sensitivity (85%) and specificity (99.8%) among all evaluated RDTs. This performance advantage is attributed to three NP-specific factors identified in the Frontiers in Public Health review (2023):
- Strong antigenicity: NP is highly immunogenic, generating robust antibody responses
- Multiple antibody binding sites: Large protein with distinct domains facilitates sandwich pair development
- Cross-species epitope sharing: Conserved regions across ZEBOV, SUDV, BDBV, and TAFV enable broad detection
"QuickNavi-Ebola achieved 85.0% sensitivity and 99.8% specificity targeting NP exclusively, outperforming all VP40-targeting RDTs in head-to-head clinical evaluations."
10. What This Means for IVD Developers
For companies and research teams developing Ebola diagnostic reagents, the NP-centric evidence base has clear actionable implications:
10.1 Antibody Development Strategy
- Target the N-terminal domain (aa 1-450) for capture antibodies — this region contains the most accessible epitopes and is essential for NP oligomerization, meaning it is consistently exposed regardless of NP's conformational state.
- Target the C-terminal domain (aa 451-739) for detection antibodies — this provides spatial separation from the capture epitope and recognizes a different structural context.
- Screen against detergent-treated NP in addition to native NP to ensure antibodies recognize the solubilized form that RDTs actually encounter.
- Validate cross-reactivity against NP from multiple Ebola species (ZEBOV, SUDV, BDBV, TAFV) to enable broad-spectrum detection.
10.2 Recombinant NP Antigen Considerations
For positive controls and assay calibration, the choice of expression system matters:
- Mammalian expression produces O-glycosylated NP closest to the native viral protein, ideal for generating antibodies that recognize natural NP epitopes
- E. coli expression produces non-glycosylated NP with high yield, suitable for epitope mapping and as an assay standard
- Insect cell expression (baculovirus) offers a balance of yield and partial post-translational modification
10.3 Assay Format Recommendations
Best Practices for NP-Targeting Ebola RDTs
Buffer: Include 0.5-2% non-ionic detergent (Triton X-100 or equivalent) to disrupt virions and EVs. Add 0.5-1% chaotropic agent if NP-RNA complex dissociation is needed for optimal epitope exposure.
Sample: Validate with EDTA whole blood (fingerstick), plasma, and serum. Whole blood is preferred for POC use.
Controls: Include a hook effect control (e.g., ultra-high NP concentration well) to flag prozone false negatives.
Limit of Detection: Target ≥; 103-104 FFU/mL (approximately Ct 30-33 on GeneXpert) to meet WHO sensitivity expectations.
Read time: 10-15 minutes is standard. Denka QuickNavi uses blue bands (colloidal gold alternative); most other tests use red bands.
11. Summary
Ebola nucleoprotein (NP) is the most strategically important antigen target for rapid diagnostic test development. The evidence is clear:
- Abundance: ~3,200 copies per virion — an 80-fold advantage over VP40 — provides the highest antigen density for antibody capture
- Multi-form availability: NP exists in blood as virion-encapsulated nucleocapsid, EV-associated cargo, and free NP-RNA complexes from cell lysis, all of which contribute to the detectable antigen pool
- Structural advantages: At 739 amino acids with distinct N- and C-terminal domains, NP offers multiple non-overlapping epitopes for sandwich assay development
- Cross-species conservation: Shared epitopes across ZEBOV, SUDV, BDBV, and TAFV enable pan-Ebola detection from a single test
- Proven clinical performance: NP-targeting QuickNavi-Ebola achieved 85% sensitivity and 99.8% specificity — the best combined performance among all evaluated Ebola RDTs
For IVD developers building next-generation Ebola diagnostics, NP remains the target of choice. The key to maximizing NP detection lies in buffer formulation that effectively solubilizes NP from all three blood forms, matched antibody pairs targeting distinct NP domains, and inclusion of hook effect controls for high-viral-load samples.
At Sekbio, we develop high-performance monoclonal antibodies and recombinant antigens for Ebola virus NP detection. Our reagents are designed for sandwich ELISA, lateral flow, and CLIA platforms — with validated cross-reactivity across Ebola species and consistent batch-to-batch performance. If you're developing an Ebola diagnostic assay, our team can support your antibody pairing and antigen supply needs.
References
- Wan Y, et al. Structure of the Ebola virus glycoprotein spike within the virion at 11 Å resolution. Scientific Reports. 2017;7:46374.
- Bharat TAM, et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. PNAS. 2012;109(11):4275-4280.
- Kubota T, et al. Structural basis for Ebola virus nucleocapsid assembly and its VP24/VP35 interactions. Nature Communications. 2025;16:2667.
- Mishima K, et al. Assembly of the Ebola virus nucleoprotein from a chaperoned 11-3-3-like fold. Cell. 2015;161(7):1536-1547.
- Noda T, et al. Functional mapping of the nucleoprotein of Ebola virus. Journal of Virology. 2006;80(8):3799-3808.
- Fitzgerald K, et al. Extracellular vesicles and Ebola virus: a new mechanism of immune evasion. Viruses. 2019;11(11):1031.
- Bettini E, et al. Diagnostics of Ebola virus. Frontiers in Public Health. 2023;11:1123024.
- Smit PW, et al. Laboratory evaluation of antigen rapid diagnostic tests to detect Ebola virus. Journal of Virological Methods. 2025;235:115661.
- Lefebvre A, et al. Clinical evaluation of the QuickNavi-Ebola rapid diagnostic test. Journal of Infectious Diseases. 2019;220(9):1459-1467. (PMC6669708)
- Zhao Y, et al. Molecular characterization of Ebola virus, immune response, and clinical management. Bulletin of the National Research Centre. 2024;48:176.